$0.781
-0.030 (-3.81%)Al cierre
Predicciones de precio
Ábrelo en la app para desbloquear previsiones a más largo plazo.
Predicción y previsión de BDRX por análisis de gráficos similares
Alphio's BDRX stock price prediction model matches the current Biodexa Pharmaceuticals PLC tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $0.80 (+1.95%). The 1-week path is $0.77 (-1.82%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
¿Debería comprar acciones de Biodexa Pharmaceuticals PLC?
Biodexa Pharmaceuticals (BDRX) is not a good buy right now due to its extremely low RSI of 7.9, indicating it is oversold, and a staggering year-to-date change of -92.94%. The stock has shown significant volatility, with a recent 5-day decline of 31.65%, suggesting a lack of stability and investor confidence. The main risk is its negative forward P/E ratio of 0, indicating no earnings growth expected in the near future, which could lead to further price declines.
BDRX cerró en $0.78 el Tuesday, tras bajar -3.81%
Biodexa Pharmaceuticals PLC (BDRX) last closed at $0.7808, losing -3.81%. These facts feed the 1-day and 1-week BDRX price prediction above.
Factores de la previsión
Los factores de la previsión de Biodexa Pharmaceuticals PLC (BDRX) combinan patrones gráficos similares, estacionalidad y medias móviles.
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bearish
SMA 200
Bearish
Patrones gráficos similares
Acciones cuya trayectoria reciente más se parece a la de BDRX, ordenadas por similitud.
Análisis de estacionalidad de BDRX
Historically the probability of a positive September return for BDRX is 0.00%. January offers the highest probability of a positive month at 36.07%, while March is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.